Bacteriophages in the Experimental Treatment of Pseudomonas aeruginosa Infections in Mice

Phage fitness may help predict phage therapy efficacy

“…The most common approach to assessing the therapeutic efficacy of a specific phage is to conduct in vivo studies. 5,[9][10][11][12][13][14][15][16][17][18][19] However, while results from such studies can directly inform us whether a specific phage is effective against the bacterial infection, often it is not immediately clear why one phage is more efficacious than the others in treating the infection, not to mention the effort and resource that are needed for screening a large number of potential candidates. A possible alternative to direct in vivo screening is to identify phage traits that can be used as a proxy for in vivo efficacy.…”

Pseudomonas Aeruginosa : Arsenal of Resistance Mechanisms, Decades of Changing Resistance Profiles, and Future Antimicrobial Therapies

“…Several studies have shown the effectiveness of phage therapy in the treatment of P. aeruginosa infections [191][192][193][194][195][196][197], although none have been clinically used in western countries. More recently, the use of targeted therapies of engineered bacterial phagemids to express beneficial antimicrobial peptides in vivo in a murine infection model has been reported [198].…”

Antimicrobial bacteriophage-derived proteins and therapeutic applications

“…It is particularly serious in individuals with cystic fibrosis, cancer, and severe burns. 96 Protein engineering has allowed endolysin-based enzymes to translocate across the outer membrane barrier of Gram-negative bacteria and control P. aeruginosa infection in animal. [50][51][52] (For details see Engineering novel endolysin constructs) Briers et al conducted a Caenorhabditis elegans nematode gut P. aeruginosa infection model to evaluate the efficacy of a polycationic nonapeptide (PCNP)-fused endolysin called Artilysin LoGT-008.…”